In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 February 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra

Related stories
Anonymization: The unicorn of privacy engineering
The hidden fragility of AI supply chains: Why traditional risk management falls short
SRB pseudonymization case withdrawn from EU General Court
The value of the DPO in navigating Chile's LPDP
Thought for the week: What a good golf lesson can teach about the impact of geopolitical risk on global data, cyber and AI

This content is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.
